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Abstract Postoperative new-onset atrial fibrillation (PNAF)
is very common after cardiac surgery and postoperative in-
flammation may contribute to PNAF by inducing atrial dys-
function. Corticosteroids reduce inflammation and may thus
reduce atrial dysfunction and PNAF development. This study
aimed to determine whether dexamethasone protects against
left atrial dysfunction and PNAF in cardiac surgical patients.
Cardiac surgical patients were randomised to a single dose of
dexamethasone (1 mg.kg−1) or placebo after inducing anaes-
thesia. Transoesophageal echocardiography was performed in
patients before and after surgery. Primary outcome was left
atrial total ejection fraction (LA-TEF) after sternal closure;
secondary outcomes included left atrial diameter and PNAF.
62 patients were included. Baseline characteristics were well
balanced. Postoperative LA-TEFwas 36.4% in the dexameth-
asone group and 40.2 % in the placebo group (difference
−3.8 %; 95 % confidence interval (CI) -9.0 to 1.4 %; P=
0.15). Postoperative left atrial diameter was 4.6 and 4.3 cm,
respectively (difference 0.3; 95 % CI −0.2 to 0.7; P=0.19).
The incidence of PNAF was 30 % in the dexamethasone
group and 39 % in the placebo group (P= 0.47).
Intraoperative high-dose dexamethasone did not protect
against postoperative left atrial dysfunction and did not reduce
the risk of PNAF in cardiac surgical patients.
Keywords Atrial fibrillation . Cardiac surgery . Left atrial
ejection fraction . Left atrial dimension . Corticosteroids
Introduction
Postoperative new-onset atrial fibrillation (PNAF) is a com-
plication occurring in 25–30 % of cardiac surgical patients.
PNAF may lead to significant morbidity, including stroke,
renal and respiratory failure, and is associated with an in-
creased mortality [1–3].
Several preoperative echocardiographic findings have been
implicated as predictors of PNAF. These predictive measures
include increased left atrial (LA) volume and dysfunction
[4–9]. A recent study showed that decreased LA total ejection
fraction (TEF) was the most potent predictor of PNAF [10].
The underlying pathophysiological mechanisms are com-
plex. Apart from pre-existing atrial dysfunction, the perioper-
ative systemic inflammatory response may play a role in
affecting atrial function, along with atrial myocardial injury
and ischaemia [11–13]. The importance of inflammatory
mechanisms is supported by several studies, demonstrating
that atrial biopsies taken during cardiac surgery show marked
oxidative damage and interstitial fibrosis [11, 13, 14].
The effects of administration of corticosteroids on the
perioperative inflammatory response during cardiac surgery
have been extensively investigated. Corticosteroids are
thought to decrease the levels of serum inflammatory markers
[15], reduce the risk of postoperative respiratory failure, and
shorten the duration of postoperative intensive care unit and
hospital stay [16, 17]. Furthermore, steroids may reduce the
incidence of PNAF. Although the latter effect seems related to
the attenuated inflammatory response [18], the exact mecha-
nisms are unclear.
This study aimed to evaluate the effect of dexamethasone
administration on postoperative LA dysfunction and
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dilatation. We hypothesised that high-dose dexamethasone
increases LA-TEF, decreases postoperative LA diameter and
protects against PNAF.
Materials and methods
Study design and patient selection
The DECS-PNAF study was a subs tudy of the
Dexamethasone for Cardiac Surgery (DECS) study. It was a
pre-planned and prospectively designed and performed
substudy in which patients with a minimum age of 18 years,
undergoing cardiac surgery, were enrolled in this multicentre
randomised, double-blind, placebo-controlled study, compar-
ing high-dose intravenous dexamethasone with placebo treat-
ment (trial registration: ClinicalTrials.gov, number
NCT00293592) [16]. DECS study patients in one of the
participating centres, i.e. University Medical Centre Utrecht,
who were scheduled for coronary artery bypass grafting
(CABG), aortic valve surgery, or a combination of these
procedures, without other concomitant valve surgery or other
additional procedures, were eligible for inclusion in this
DECS-PNAF study. Patients with either a history of atrial
fibril lation, a contraindication for intraoperative
transoesophageal echocardiography, or a preoperative cardiac
rhythm other than sinus rhythm, were not eligible for
inclusion.
The research ethics committee of the University Medical
Center Utrecht approved the research protocol. All patients
provided written informed consent before randomisation. The
study was performed in accordance with the Medical
Research Involving Human Subjects Act (WMO) and institu-
tional regulations and guidelines.
Intervention
Patients were randomised to receive either dexamethasone or
placebo treatment. Dexamethasone (1 mg.kg−1 with a maxi-
mum of 100 mg) or placebo was administered as a single
intravenous injection after induction of anaesthesia, but before
commencement of cardiopulmonary bypass. Comprehensive
information about the randomisation methods has been pub-
lished previously [16].
Primary and secondary outcomes
The primary endpoint of this study was the LA-TEF at the end
of the surgical procedure. Secondary endpoints included LA
diameter, LA area, maximum and minimum LAvolume in the
cardiac cycle, left atrial appendage (LAA) area and velocity
and left pulmonary vein systolic/diastolic (S/D) ratio at the
same time point. We also evaluated the occurrence of PNAF
during the first 5 days after surgery.
Data collection
Baseline patient characteristics and surgical characteristics
were prospectively collected as part of the DECS study [16].
For the present substudy, patients underwent transoesophageal
echocardiography after induction of anaesthesia, and after
sternal closure at the end of the operation, while the patient
was in a supine position. The required images were stored and
analysed offline by two independent blinded observers, using
the Philips XCELERA Cardiology image (Version 3.2) soft-
ware package. All measurements were done twice and
averaged.
LA diameter was measured from the posterior LA wall to
the mitral annulus, at the end of ventricular systole in the mid-
oesophageal long-axis viewwith the transducer array at ~120°
[19, 20]. LA volume was assessed by the area-length method
from both the mid-oesophageal four-chamber and two-
chamber views, with LA size being optimised in both views.
Biplane LA volume was calculated using Simpson’s method.
The LAvolume was measured at both the end of diastole (left
atrial end-diastolic volume, being maximum LAV), and at the
end of systole (left atrial end-systolic volume, being minimum
LAV) [20]. LA-TEF was calculated using the following for-
mula: (((LAVmax - LAVmin)/LAVmax)×100 %). In patients
in whom the entire dimensions or volume of the LAwere not
visible in the scan sector, measurements were traced to the
edge of the field of view. The LAA was imaged in the mid-
oesophageal two-chamber view. The LAA area was calculated
using Simpson's method, at the end of ventricular systole, and
peak velocity was measured by pulse wave Doppler, with the
pulsed Doppler sample volume placed in the LAA cavity.
Peak flow velocity in the left pulmonary vein was recorded
and measured using a biphasic systolic and diastolic velocity
wave. The S/D ratio was calculated afterwards.
The occurrence of PNAF was evaluated with continuous
Holter monitoring (leads V1-V5) for the first 5 days postop-
eratively in all patients. The occurrence of PNAF was defined
as the occurrence of any episode of atrial fibrillation or atrial
flutter during any of these five postoperative days.
Statistical analysis
Normally distributed continuous variables are presented as
means with standard deviations (±SD). Data in both groups
were compared using an independent t-test. Continuous data
that were not normally distributed are presented as medians
with interquartile range and were compared using a Mann–
Whitney U-test. Dichotomous characteristic variables are pre-
sented as absolute numbers with percentages and were com-
pared using a χ2 test. We calculated mean differences with
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95 % confidence intervals (CIs), for continuous and
dichotomous outcomes, respectively. In addition to the
analyses based on the randomisation to dexamethasone
or placebo, we evaluated the association between LA-
TEF and PNAF using an independent t-test. A p-value<
0.05 was considered significant in the analysis models.
Statistical analysis was performed using IBM SPSS
version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
The DECS-PNAF transoesophageal echocardiography
substudy included 62 patients (Fig. 1). Patients in the two
study groups were comparable with no statistical differences
in baseline demographic, clinical, and surgical aspects
(Table 1).
At the beginning of the operation, after induction of anaes-
thesia, echocardiographic data were collected in only 22 pa-
tients in each group. This is because preoperative ultrasound
was not routinely assessed in all patients, as was the case with
postoperative ultrasound. There were no differences in any of
the obtained echocardiographic parameters between the dexa-
methasone group and the placebo group (Table 2). Also, no
differences were found in preoperative and postoperative LA
dimensions and function between patients undergoing valve
surgery or CABG in both the placebo and dexamethasone
group.
Primary outcome
The mean LA-TEF after sternal closure was 36.4 % (±11.9 %)
in the dexamethasone group and 40.2 % (±7.9 %) in the
placebo group (mean difference −3.8 %; 95 % CI −9.0 to
1.4 %; P=0.15) (Table 3).
Secondary outcomes
After sternal closure, there were no differences in LA diame-
ter, LA area, maximum and minimum volume of the left
atrium, LAA area and velocity, and left pulmonary S/D ratio
between the two groups (Table 3).
PNAF occurred in 21 of the 62 patients (34 %) and was
most commonly detected on the third postoperative day, with
a median duration of1 day. In the dexamethasone group, nine
patients developed PNAF (30%), while 12 patients developed
PNAF in the placebo group (39 %) (P=0.47). In patients who
developed PNAF, mean LA-TEF was 38.6 % (±9.1 %), as
compared with 38.0 % (±10.9 %) in patients in whom PNAF
did not occur (mean difference 0.6; 95 % CI: −4.6 to 5.9; P=
0.81).
Discussion
In this study we evaluated the effect of high-dose intraopera-
tive dexamethasone on echocardiographic measures of LA
Fig. 1 Enrolment flowchart. In
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function, as a possible determinant of the risk for atrial fibril-
lation after cardiac surgery. No effect of dexamethasone on
LA ejection fraction or dimensions was found when compared
with placebo. Also, dexamethasone did not significantly re-
duce the risk of PNAF.
Atrial fibrillation is a very common cardiovascular disease
with a lifetime risk in the general Dutch population of 25–
30 % [21]. In the cardiac surgical population, its incidence is
very high, being up to a third of all patients developing PNAF,
and older age is still the only preoperative risk factor that has
been consistently shown to predict the occurrence of PNAF
[2, 3]. Nonetheless, LA dimensions and function have been
implicated to be predictors of PNAF in the postoperative
setting in several studies [9, 10]. Preoperative LA-TEF was
shown by Haffajee et al. to predict PNAF even better than LA
volume or diameter [10]. Osranek et al. found that preopera-
tive maximum LA volume (32 ml/m2) was an important
predictor of PNAF [9]. However, Gibson et al. did not confirm
this [6].
The mechanisms that contribute to the development of LA
dysfunction after cardiac surgery are still not entirely clear. In
patients with a positive fluid balance, the left atrium is often
exposed to a higher preload postoperatively when compared
with the preoperative period. Additionally, due to surgical
Table 1 Demographic, clinical,




inhibitors; ARBs: angiotensin II
receptor blockers; BSA: body
surface area; CABG: coronary
artery bypass graft; CPB:
cardiopulmonary bypass; IQR,
interquartile range; N: number. SI
conversion: To convert creatinine
to mg/dL, multiply by 0.0113
αData are shown as N (%) unless
otherwise specified
β BSA calculated using the
Haycock formula
γ Definition of left ventricular
function class: good, ejection
fraction of >50 %, moderate,
ejection fraction of 30–50 %;
and poor, ejection fraction of
<30 %
δ Higher EuroScores present
increased risk of perioperative
mortality
ζValve surgery includes aortic
valve surgery
Characteristics Dexamethasone N=30 Placebo N=32
Demographics
Age, mean (SD), years 70.4 (9.1) 68.9 (9.0)
Male sex 24 (80) 23 (72)
BMI, mean (SD), kg/m2 27.96 (4.79) 26.83 (3.28)
BSA, mean (SD), m2, β 2.04 (0.20) 1.97 (0.17)
Coexisting medical conditions
Hypertension 18 (60) 20 (63)
Diabetes mellitus 7 (23) 3 (9)
Treatment for pulmonary disease 2 (7) 7 (22)
Peripheral vascular disease 5 (17) 8 (25)
Preoperative creatinine, mean (SD), μmol/l 89.3 (18.6) 92.8 (18.6)
Recent myocardial infarction 6 (20) 5 (16)
Left ventricular function, Good, γ 21 (70) 21 (66)
EuroScore, median (IQR)c, δ 5 (4–7) 5 (3–7)
Preoperative medication
Statin 28 (93) 22 (69)
Βeta blocker 22 (73) 20 (63)
Diuretics 8 (27) 8 (25)
Aspirin 23 (77) 24 (75)
Calcium entry blockers 25 (83) 21 (66)
Nitrates 15 (50) 11 (34)
ACEI/ARBs 18 (60) 13 (41)
Valve surgery, ζ 15 (50) 16 (50)
Duration of procedure, (SD), min 194 (18) 170 (10)
Duration of CPB, (SD), min 116 (12) 92 (7)
Duration of cross clamp time, (SD), min 85 (8) 70 (5)
Table 2 Comparison of
preoperative echocardiographic
parameters in the dexamethasone
and placebo groups (N=44). Data
shown in means±SD
Abbreviations: CI: confidence
interval; LA: left atrial; N:
number; SD: standard deviation;









95 % CI of
difference
P Value
LA-TEF, % 41.1 (12.4) 42.2 (14.0) −1.1 −9.2 to 6.9 0.77
LA diameter, cm 4.2 (0.7) 4.3 (0.8) −0.1 −0.6 to 0.4 0.11
LA area, cm2 15.3 (5.0) 14.9 (4.6) 0.4 −2.4 to 3.4 0.75
LA max, ml 43.0 (19.6) 42.8 (18.6) 0.2 −11.4 to 11.9 0.97
LA min, ml 26.9 (16.2) 26.0 (15.2) 0.9 −8.6 to 10.5 0.85
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trauma, the left atrium is exposed to a systematic inflamma-
tory response. The higher preload and the systemic inflamma-
tionmay result in atrial dilatation and fibrotic infiltrates. These
changes lead to temporary electromechanical and morpholog-
ical changes in the atrial myocardium and can subsequently
cause the formation of micro re-entrant pathways [14, 22].
Several anti-inflammatory drugs have been studied to reduce
PNAF, e.g. statins and corticosteroids. Large observational
studies and trials with statins for this indication have
shown conflicting results, but in a recent systematic re-
view it was concluded that statins have positive effects on
protecting against PNAF [23–25]. In the current study the
authors focused on investigating corticosteroids and their
role in reducing PNAF. Corticosteroids are known to
inhibit both inflammation and tissue changes in the heart,
by suppressing inflammation-induced proliferation of
myocardial fibroblasts as well as by preventing the acti-
vation of ERK1/2 and NF-κB [26, 27]. Several clinical
studies have shown that intraoperative corticosteroids re-
duce the risk of PNAF and the consistency of these
findings has recently been confirmed by several reviews
and meta-analyses [17, 25, 28].
In this study, dexamethasone did not have any demonstra-
ble effects on TEF, LA and LAA dimensions. These findings
could be due to the fact that we have missed an actual effect of
dexamethasone because the number of patients included in
this study was relatively small. On the other hand, other
factors could have contributed to missing an effect. The rela-
tively high age of the study population (mean age of 70) could
have contributed, since ageing often leads to a permanent loss
of myocardial muscle fibres and an increase in fibrosis,
resulting in irreversible atrial remodelling which may not be
influenced by dexamethasone [29]. Also, LA dimensions and
function strongly depend on loading conditions. Most patients
are intravascularly well loaded after the operation and most
are on inotropic support, which might have confounded the
effect of dexamethasone on the left atrium. However, it seems
very reasonable to assume that dexamethasone does not have
an effect on LA-TEF at all. Moreover, no association between
LA-TEF and PNAF could be demonstrated, and the incidence
of PNAF was not reduced by dexamethasone. The latter is
contradictory to several previous studies looking at the effects
of steroids on PNAF, although it is in line with the findings of
the DECS trial, where no effect of treatment on PNAF could
be demonstrated in 4482 patients.
This study demonstrates that PNAF is a complex arrhyth-
mia with multiple mechanisms underlying its pathology,
whereby atrial remodelling through an inflammatory pathway
may only play a minor role. Future studies should investigate
atrial biopsies to attempt to elucidate subtle and delicate
pathophysiological inflammatory and microfibrotic changes
in the atrial myocardium, as well as the effects on this of anti-
inflammatory agents.
Strengths and limitations
The strengths of this study include the randomised double-
blinded placebo-controlled design, which allowed for strict
distribution of the patient’s clinical and demographic charac-
teristics. Continuous Holter monitoring for 5 days postopera-
tively ensured that all PNAF episodes could be detected for
accurate quantification.
A limitation of this study is that the sample size was
small. Another limitation is that with transoesophageal
echocardiography there might be an underestimation of
LA dimension. As this holds for both study groups, and
for the measurements obtained before and after surgery,
we do not expect an effect on the study results obtained.
Another limitation is the fact that LA-TEF was measured
and calculated based on transoesophageal echocardiogra-
phy images, using the same methods and mathematical
formula that have been used in previous studies using
transthoracic echocardiography. Although these methods
have not been well validated in transoesophageal echo-
cardiography, the potential error is probably the same for
both groups.
Table 3 Comparison of postoperative echocardiographic parameters in the dexamethasone and placebo groups (N=62). Data shown in means±SD
Ultrasound parameter Dexamethasone (N=30) Placebo (N=32) Mean difference 95 % CI of Difference P Value
LA-TEF, % 36.4 (11.9) 40.2 (7.9) −3.8 −9.0 to 1.4 0.15
LA diameter, cm 4.6 (0.8) 4.3 (0.9) 0.3 −0.2 to 0.7 0.19
LA area, cm2 16.0 (5.0) 16.4 (5.9) −0.4 −3.1 to 2.4 0.81
LA max, ml 31.0 (12.3) 31.3 (13.9) −0.3 −7.0 to 6.3 0.91
LA min, ml 19.7 (10.7) 18.8 (9.8) 0.9 −4.3 to 6.2 0.73
LAA area, cm2 2.9 (0.9) 2.7 (0.8) 0.2 −0.3 to 0.6 0.47
LAA velocity, cm/s 57.3 (19.6) 58.9 (16.3) −1.6 −11.6 to 8.4 0.75
Left pulmonary vein S/D ratio 1.3 (0.2) 1.5 (0.4) −0.2 −0.4 to 0.1 0.17
Abbreviations: CI: confidence interval; LA: left atrial; LAA: left atrial appendage; N: number; S/D ratio: systolic/diastolic ratio; SD: standard deviation;
TEF: total ejection fraction
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Conclusion
Intraoperative high-dose dexamethasone did not have any
protective effect on postoperative LA-TEF or dimension and
did not reduce the risk of PNAF in cardiac surgical patients.
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